211 related articles for article (PubMed ID: 29103158)
1. SIRT3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer.
Xiong Y; Wang L; Wang S; Wang M; Zhao J; Zhang Z; Li X; Jia L; Han Y
J Cancer Res Clin Oncol; 2018 Feb; 144(2):189-198. PubMed ID: 29103158
[TBL] [Abstract][Full Text] [Related]
2. Minnelide/Triptolide Impairs Mitochondrial Function by Regulating SIRT3 in P53-Dependent Manner in Non-Small Cell Lung Cancer.
Kumar A; Corey C; Scott I; Shiva S; D'Cunha J
PLoS One; 2016; 11(8):e0160783. PubMed ID: 27501149
[TBL] [Abstract][Full Text] [Related]
3. SIRT3 is correlated with the malignancy of non-small cell lung cancer.
Xiong Y; Wang M; Zhao J; Wang L; Li X; Zhang Z; Jia L; Han Y
Int J Oncol; 2017 Mar; 50(3):903-910. PubMed ID: 28197634
[TBL] [Abstract][Full Text] [Related]
4. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
Dragoj M; Bankovic J; Sereti E; Stojanov SJ; Dimas K; Pesic M; Stankovic T
Invest New Drugs; 2017 Dec; 35(6):718-732. PubMed ID: 28733702
[TBL] [Abstract][Full Text] [Related]
5. Sirtuin 3 induces apoptosis and necroptosis by regulating mutant p53 expression in small‑cell lung cancer.
Tang X; Li Y; Liu L; Guo R; Zhang P; Zhang Y; Zhang Y; Zhao J; Su J; Sun L; Liu Y
Oncol Rep; 2020 Feb; 43(2):591-600. PubMed ID: 31894331
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
Shen WM; Yin JN; Xu RJ; Xu DF; Zheng SY
Kaohsiung J Med Sci; 2019 Jul; 35(7):401-407. PubMed ID: 31001918
[TBL] [Abstract][Full Text] [Related]
7. SIRT3 increases cisplatin sensitivity of small-cell lung cancer through apoptosis.
Guo R; Li Y; Xue Y; Chen Y; Li J; Deng X; Su J; Liu Y; Sun L
Gene; 2020 Jun; 745():144629. PubMed ID: 32229158
[TBL] [Abstract][Full Text] [Related]
8. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC).
Zhang JG; Wang JJ; Zhao F; Liu Q; Jiang K; Yang GH
Clin Chim Acta; 2010 Jun; 411(11-12):846-52. PubMed ID: 20223231
[TBL] [Abstract][Full Text] [Related]
10. The Expression and Related Clinical Significance of SIRT3 in Non-Small-Cell Lung Cancer.
Yang GC; Fu BC; Zhang DY; Sun L; Chen W; Bai L; Gao T; Lu HG; Wang ZY; Kong QQ; Qiu L; Tian H
Dis Markers; 2017; 2017():8241953. PubMed ID: 28947845
[TBL] [Abstract][Full Text] [Related]
11. Sirt3 is a tumor suppressor in lung adenocarcinoma cells.
Xiao K; Jiang J; Wang W; Cao S; Zhu L; Zeng H; Ouyang R; Zhou R; Chen P
Oncol Rep; 2013 Sep; 30(3):1323-8. PubMed ID: 23842789
[TBL] [Abstract][Full Text] [Related]
12. SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Li Z; Huang J; Yuan H; Chen Z; Luo Q; Lu S
Oncotarget; 2016 Apr; 7(14):18927-39. PubMed ID: 26942878
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway.
Ai X; Mao F; Shen S; Shentu Y; Wang J; Lu S
BMC Cancer; 2018 Apr; 18(1):407. PubMed ID: 29642873
[TBL] [Abstract][Full Text] [Related]
14. SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2.
Li H; Feng Z; Wu W; Li J; Zhang J; Xia T
Int J Oncol; 2013 Nov; 43(5):1420-30. PubMed ID: 24042441
[TBL] [Abstract][Full Text] [Related]
15. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
16. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.
Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
Cancer Biother Radiopharm; 2012 May; 27(4):227-33. PubMed ID: 22489661
[TBL] [Abstract][Full Text] [Related]
17. Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.
Stankovic T; Milinkovic V; Bankovic J; Dinic J; Tanic N; Dramicanin T; Tanic N
Biomed Pharmacother; 2014 Jun; 68(5):521-6. PubMed ID: 24767865
[TBL] [Abstract][Full Text] [Related]
18. SirT3 and p53 Deacetylation in Aging and Cancer.
Chen J; Wang A; Chen Q
J Cell Physiol; 2017 Sep; 232(9):2308-2311. PubMed ID: 27791271
[TBL] [Abstract][Full Text] [Related]
19. CRIF1 promotes the progression of non-small-cell lung cancer by SIRT3- mediated deacetylation of PYCR1.
Wang Q; Xie Z; Li C; Xu C; Ding C; Ju S; Chen J; Cui Z; Chen C; Gu B; Wei T; Zhao J
J Mol Histol; 2022 Aug; 53(4):657-667. PubMed ID: 35716330
[TBL] [Abstract][Full Text] [Related]
20. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN.
Xue X; Liu Y; Wang Y; Meng M; Wang K; Zang X; Zhao S; Sun X; Cui L; Pan L; Liu S
Oncotarget; 2016 Dec; 7(51):84508-84519. PubMed ID: 27811366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
